Related Experiment Videos
Cancer research 2000: drug resistance, new targets and drugs in development
Henk J. Broxterman1, Nafsika Georgopapadakou
1Department of Medical Oncology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
Abstract:
The 91st Annual Meeting of the American Association for Cancer Research (AACR) provided the latest developments in cancer research. We highlight here presentations on resistance mechanisms (tumor microenvironment, efflux pumps, apoptosis), new targets and drugs in development (signal transduction, cell cycle, apoptosis, microtubules, topoisomerases) and new technologies (the cancer genome anatomy project, the human genome project, proteomics). The importance of signaling pathways or networks ('cell context') in defining the role of particular proteins was brought up in several presentations. A summary of specific drugs in development is also included in this report. Copyright 2000 Harcourt Publishers Ltd.
Insights
The 91st American Association for Cancer Research meeting showcased advancements in cancer research, including drug development, resistance mechanisms, and new technologies like proteomics and genome projects. Key findings emphasize the role of cell signaling pathways in cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- The American Association for Cancer Research (AACR) annual meeting is a premier forum for presenting cutting-edge cancer research.
- Understanding cancer progression involves studying resistance mechanisms, novel therapeutic targets, and emerging technologies.
Purpose of the Study:
- To summarize key developments presented at the 91st AACR Annual Meeting.
- To highlight advancements in cancer resistance mechanisms, drug development, and technological innovations.
Main Methods:
- Review of presentations from the 91st AACR Annual Meeting.
- Categorization of research into resistance mechanisms, drug targets, and new technologies.
- Emphasis on the role of cellular context in protein function.
Main Results:
- Key resistance mechanisms discussed include the tumor microenvironment, efflux pumps, and apoptosis.
- New targets and drugs in development focus on signal transduction, cell cycle, apoptosis, microtubules, and topoisomerases.
- Emerging technologies include the Cancer Genome Anatomy Project, Human Genome Project, and proteomics.
Conclusions:
- Signaling pathways ('cell context') are crucial for defining protein roles in cancer.
- The presented research offers insights into current and future cancer treatment strategies.
- The report provides a summary of specific drugs currently in development for cancer therapy.